Award recognizes scientists’ trust in CST’s phospho-specific antibodies, reflected in thousands of research citations
Danvers, MA, USA, March 19, 2026–Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced it has been named the CiteAb 2026 Phospho Antibody Supplier of the Year. The award recognizes the company with the most citations for phospho-specific antibodies over the past year, underscoring CST’s long-standing leadership in developing post-translational modification (PTM) reagents and its lasting impact on the global life sciences industry.
“CST was founded by researchers who understood early on how phospho-specific antibodies would fundamentally change how we study cellular signaling in health and disease,” says Roberto (Roby) Polakiewicz, PhD, Chief Scientific Officer at Cell Signaling Technology. “From our first PTM antibodies to today’s broad portfolio, our mission remains the same—to develop rigorously validated reagents that help scientists interrogate signal transduction pathways in normal biology and disease with confidence.”
CiteAb analyzes citation data from millions of scientific publications to identify antibody and reagent suppliers making the biggest impact in key research areas. Drawing from over 380 global antibody suppliers and nearly 8 million antibodies, CST consistently stands out for having more reagents in CiteAb’s top-cited lists than any other antibody company.
“It is a pleasure to recognize Cell Signaling Technology in the ‘Phospho Antibody Supplier of the Year’ Award, marking their success in providing highly-cited phospho antibodies to researchers,” said Dr Andy Chalmers, CEO and co-founder of CiteAb. “Producing high-quality antibodies against proteins with post-translational modifications is a demanding process and their work to produce and characterise these reagents, while often unseen, underpins important science happening in labs around the world. Congratulations to the entire team at CST.”
CST’s portfolio includes thousands of rigorously validated recombinant monoclonal antibodies and high-quality reagents supporting research in oncology, immunology, neuroscience, metabolism, fibrosis, and epigenetics, with PTM and phospho-specific antibodies at the core. The company has also pioneered enabling technologies, including PTMScan proteomics, first-to-market CUT&RUN reagents, SignalStar® Multiplex IHC assays for spatial biology, and InTraSeq™ Single Cell Analysis Reagents, which allow simultaneous quantification of proteins and RNA at the single cell level. Together with resources such as the PhosphoSitePlus® database and The Kinase Library prediction tool, these innovations help scientists map signaling networks, discover novel PTM sites, and identify new therapeutic targets.
In recent years, CST has been named Recombinant Antibody Supplier of the Year (2025 and 2022), received the prestigious CiteAb Innovation Award for Anti-CAR Linker Antibodies and the InTraSeq Single Cell Analysis technology, and has been named the supplier succeeding in multiple categories, including Cancer Research, Genetics Research, Alzheimer’s Research, and more.
Learn more about CiteAb and the 2026 Awards by visiting: https://www.citeab.com/awards
CiteAb provides world-class data that accelerates scientific research. Our industry- leading data collection technology combines machine learning and extensive human reviewing to identify and understand reagent use from scientific publications. This highly accurate data is used to power all of our products, which help researchers find and suppliers sell the best reagents. Our search engine ranks products by citations, fundamentally changing the way researchers find products for their experiments, and our data-based products are used to inform suppliers globally. Over 4 million pages of information were served to CiteAb users in the last year, from searches of over 6.8 million reagents. We are a committed group of biologists and computer scientists dedicated to helping the world's best scientists and suppliers tackle the big problems in life science research. For more information, visit www.citeab.com
Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our customers, our communities, and our planet. www.cellsignal.com
CST Contact
CST Media and Press
Rebecca J. Reppucci, MBA
Cell Signaling Technology
Senior Director, Global Marketing Communications
Phone: +1-978-880-3334
Email: [email protected]
